Skip to content
value.today

Gilgamesh Pharmaceuticals, Inc.

Total raised
$51 M
3 rounds on record
Latest round
$14 M
May 2022
First round on record
Apr 2020
Today
Acquired
Acquired by AbbVie Inc.

Acquired

Matched to this startup by its exact name; the buyer's report is the source.

Acquisition of Gilgamesh Pharmaceuticals, Inc.
AcquiredBuyerAcquisition dateCompletionPriceStakeSource
Gilgamesh Pharmaceuticals, IncAbbVie Inc.2025—$906 M—Annual report

Funding rounds

3 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Gilgamesh Pharmaceuticals, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
May 2022$14 MNo. 3$10 to $50 million

Gilgamesh Pharmaceuticals, Inc.: Raise no. 3, May 2022

Investors in this round

14 investors had bought by the notice of May 19, 2022: 14 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 1 investor is named for Gilgamesh Pharmaceuticals, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$14 M of $50 M offered; $36 M still to sell
Smallest investment taken
$50,000
What was sold
equity, other: Shares of preferred stock of Issuer (Preferred Shares), and the shares of capital stock of the Issuer into which the Preferred Shares may convert.
Exemption claimed
  • Rule 506(c): may be advertised publicly; every buyer must be a verified accredited investor
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Andrew Kruegel · Executive Officer, Director
  • Gerard Marek · Executive Officer
  • Jonathan Sporn · Executive Officer, Director
  • Laszlo Kiss · Executive Officer
  • Thomas Kevin Murphy · Executive Officer
  • Yoni Falkson · Executive Officer
  • Amy Kruse · Director
  • Gaetano Kevin Crupi · Director
  • Phil Skolnick · Director
  • Robert Berman · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the use of proceeds: “Some of the proceeds will be used to pay the salaries of the officers of the Issuer in the ordinary course of business.”

Signed by John Fallone, Attorney for Issuer. Newest notice filed May 19, 2022. Read the notice at the SEC.

equitySEC
Apr 2021$35 MNo. 2$10 to $50 million

Gilgamesh Pharmaceuticals, Inc.: Raise no. 2, Apr 2021

Investors in this round

66 investors had bought by the notice of May 6, 2021: 66 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 1 investor is named for Gilgamesh Pharmaceuticals, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$35 M of $35 M offered
Smallest investment taken
$10,000
What was sold
equity, other: In addition to the shares of preferred stock sold by the Issuer, the shares of Issuer capital stock into which such shares of preferred stock may convert.
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
$630,000 (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Andrew Kruegel · Executive Officer, Director
  • Jonathan Sporn · Executive Officer, Director
  • Amy Kruse · Director · Kruse was appointed as a Director, effective upon closing of the transaction.
  • Dalibor Sames · Director · Sames resigned as a Director, effective upon closing of the transaction.
  • Robert Berman · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the use of proceeds: “Some of the proceeds will be used to pay the salary of executive officers of the Issuer.”

Signed by John Fallone, Attorney for Issuer. Newest notice filed May 6, 2021. Read the notice at the SEC.

equitySEC
Apr 2020$2 MNo. 1$2 to $10 million

Gilgamesh Pharmaceuticals, Inc.: Raise no. 1, Apr 2020

Investors in this round

25 investors had bought by the notice of Jul 10, 2020: 25 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 1 investor is named for Gilgamesh Pharmaceuticals, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$2 M (amount offered: indefinite)
Smallest investment taken
no minimum stated
What was sold
equity, debt
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Andrew Kruegel, Ph.D. · Executive Officer
  • Jonathan Sporn, M.D. · Executive Officer, Director · President and Chief Executive Officer
  • Thomas Kevin Murphy, Ph.D. · Executive Officer

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Jonathan Sporn, M.D., President and Chief Executive Officer. Newest notice filed Jul 10, 2020. Read the notice at the SEC.

equity, debtSEC

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Gilgamesh Pharmaceuticals, Inc. chose not to state its revenue in its newest notice of a funding round (May 2022).

    SEC Form D · May 2022

  • The industry group it chose in its notices: Pharmaceuticals.

    SEC Form D · May 2022

In its own words

How the company describes itself to search engines on its website, word for word.

“A clinical-stage neuroscience biotech developing innovative new chemical entities that transform the treatment paradigm of psychiatric disease.”

As of Nov 15, 2026

Products and services#

No products or services on record: its website does not describe any in structured form (a page that declares itself a product or service), and Wikidata lists none.

Investors#

1 named in official filings. Open an investor to see everything it has backed.

Investors in Gilgamesh Pharmaceuticals, Inc.
InvestorKindAmountRoundRoleSource
Ayuh VenturesVenture capitalnot statednot statedInvestorWikidata

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Gilgamesh Pharmaceuticals, Inc.
NameRoleNamed in
Andrew KruegelExecutive officerMay 2022
Gerard MarekExecutive officerMay 2022
Jonathan SpornExecutive officerMay 2022
Laszlo KissExecutive officerMay 2022
Thomas Kevin MurphyExecutive officerMay 2022
Yoni FalksonExecutive officerMay 2022
Andrew Kruegel, Ph.D.Executive officerJul 2020
Jonathan Sporn, M.D.President and Chief Executive OfficerJul 2020
Thomas Kevin Murphy, Ph.D.Executive officerJul 2020
Amy KruseDirectorMay 2022
Andrew KruegelDirectorMay 2022
Gaetano Kevin CrupiDirectorMay 2022
Jonathan SpornDirectorMay 2022
Phil SkolnickDirectorMay 2022
Robert BermanDirectorMay 2022
Dalibor SamesSames resigned as a Director, effective upon closing of the transaction.May 2021
Jonathan Sporn, M.D.President and Chief Executive OfficerJul 2020

About

American clinical-stage neuroscience biotechnology company.

Acquired (Jan 1, 2025). Acquired by AbbVie Inc..